NEK1

Serine/threonine-protein kinase Nek1

17,893 patent compounds predicted against NEK1, 12,706 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL857853	0.53	7/20
SCHEMBL858018	0.53	7/20
SCHEMBL101575	0.51	6/20
SCHEMBL857203	0.50	6/20
SCHEMBL857394	0.61	5/20
SCHEMBL624237	0.58	5/20
SCHEMBL625689	0.58	5/20
SCHEMBL412853	0.58	5/20
SCHEMBL857745	0.56	5/20
SCHEMBL410023	0.56	5/20
SCHEMBL857267	0.55	5/20
SCHEMBL415685	0.54	5/20
SCHEMBL858043	0.50	5/20
SCHEMBL101730	0.49	5/20
SCHEMBL410498	0.49	5/20
SCHEMBL850817	0.49	5/20
SCHEMBL148296	0.46	5/20
SCHEMBL856972	0.61	4/20
SCHEMBL857604	0.57	4/20
SCHEMBL100470	0.47	4/20

Germline variants in NEK1 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full NEK1 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to NEK1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)	PHASE1/PHASE2	NOT_YET_RECRUITING
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...	PHASE2	COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
A Phase II Single-arm Intervention Trial of Nelfinavir in Patients With Grade 2/3 or 3 Cervical Intraepithelial Neoplasia	PHASE2	WITHDRAWN
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers	PHASE1/PHASE2	RECRUITING
Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations	PHASE2	COMPLETED
LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer	PHASE2	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b	PHASE1	COMPLETED
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy	PHASE1	RECRUITING
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers	PHASE1	COMPLETED
Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel	PHASE1	COMPLETED
Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy	PHASE1	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212	PHASE1	COMPLETED
Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer	PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
The Roles of Neutrophil Elastase in Lung Cancer	nan	UNKNOWN
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients	nan	RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children	nan	COMPLETED
Molecular Phenotype Changes and Personalized Treatment for CRPC	nan	UNKNOWN
Muscle Wasting in Cancer (MWIC)	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a NEK1 binder may also engage these)

Protein	Name	Similarity
P51954	—	1.000	P51954 →
Q498L0	—	0.995	Q498L0 →
Q9JIH7	—	0.994	Q9JIH7 →
A2RUV4	—	0.994	A2RUV4 →
Q9HCH5	—	0.994	Q9HCH5 →
Q8IZ21	—	0.993	Q8IZ21 →
PEAK1	Inactive tyrosine-protein kinase PEAK1	0.993	landscape →
Q8BUZ1	—	0.993	Q8BUZ1 →
Q811D2	—	0.993	Q811D2 →
Q95QY7	—	0.992	Q95QY7 →
BMP2K	BMP-2-inducible protein kinase	0.992	landscape →
A6QP06	—	0.992	A6QP06 →
Q9H329	—	0.991	Q9H329 →
O44740	—	0.991	O44740 →
G5EED4	—	0.991	G5EED4 →
WNK3	Serine/threonine-protein kinase WNK3	0.991	landscape →
Q9VR99	—	0.991	Q9VR99 →
O14148	—	0.991	O14148 →
Q751A7	—	0.991	Q751A7 →
Q8C0P0	—	0.991	Q8C0P0 →
Q2PFD7	—	0.990	Q2PFD7 →
Q99550	—	0.990	Q99550 →
Q15154	—	0.990	Q15154 →
A5WV69	—	0.990	A5WV69 →
Q9JIF9	—	0.990	Q9JIF9 →
Q6YXZ4	—	0.990	Q6YXZ4 →
Q6BKC2	—	0.990	Q6BKC2 →
O60129	—	0.990	O60129 →
Q09377	—	0.990	Q09377 →
P0DJD0	—	0.990	P0DJD0 →